| Document |
Document Title |
|
WO/2021/216494A1 |
The invention provides compositions and methods for treatment of gastrointestinal bleeding, such as upper GI bleeding. In certain aspects, the invention provides topical formulations that stop bleeding in the GI tract by forming a gel wh...
|
|
WO/2021/210776A1 |
The present invention provides iron oxide magnetic particles comprising iron oxide and MXn, wherein M comprises at least one selected from the group consisting of Cu, Sn, Pb, Mn, Ir, Pt, Rh, Re, Ag, Au, Pd and Os, X comprises at least on...
|
|
WO/2021/209441A1 |
The invention relates to a dermatological composition comprising at least one polar extract of an alga of the genus Skeletonema or a photosensitizer derived therefrom, for the treatment of acne or bacterial infections, as well as to a me...
|
|
WO/2021/211909A2 |
The present invention relates to the treatment of neurodegenerative diseases by administering an endothelial interrupter. More specifically, the endothelial interrupter is a direct thrombin inhibitor.
|
|
WO/2021/211921A2 |
Embodiments of the present disclosure relate to a method of preventing and/or reducing C. difficile colonization of a surface. In certain embodiments, the aptamer can be used to kill and/or deactivate a C. difficile spore. In certain emb...
|
|
WO/2021/207691A1 |
Disclosed herein are phthalocyanine dyes, and conjugates thereof, useful as fluorescent reporters for bioassays, for optical imaging and as therapeutic conjugates as the photosensitizing agents in light-based therapies including photoimm...
|
|
WO/2021/207723A2 |
Provided herein are methods of treating diabetic kidney disease comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, and a SGLT-2 inhibitor to a subject in need thereof.
|
|
WO/2021/206078A1 |
The present invention addresses the problem of providing a medicine for killing tumor cells, said medicine having few side effects. According to the present invention, provided is a medicine, said medicine comprising a conjugate of a sub...
|
|
WO/2021/207566A1 |
Provided herein are aqueous solutions and pharmaceutical compositions comprising ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not li...
|
|
WO/2021/207213A2 |
Methods of preventing or treating infection by a SARS-CoV-related betacoronavirus are described. The methods include administering to a patient at risk of being infected by a SARS-CoV-related betacoronavirus or suffering from SARS-CoV-re...
|
|
WO/2021/201451A1 |
A phospholipid-photothermal nanoparticle according to the present invention has a cancer cell surface protein-specific antibody bound to the surface thereof, and thus can specifically bind to cancer cells, has a small particle size and e...
|
|
WO/2021/201426A1 |
The technology disclosed in the present specification relates to a nanoparticle provision medium for thermotherapy. The nanoparticle provision medium for thermotherapy according to an embodiment may be formed so as to capture nanoparticl...
|
|
WO/2021/202990A2 |
The invention features the use of a p38 inhibitor for the treatment and prophylaxis of severe symptoms of betacoronavirus infections, such as infections by SARS-CoV-2, SARS-CoV-1, MERS-CoV, and related viruses.
|
|
WO/2021/202780A2 |
Methods and compositions for treating cancer are disclosed herein. The methods may comprise use of therapeutically effective amounts of one or more therapeutic agents to cause a difference in expression or activity of protein kinase, mem...
|
|
WO/2021/202381A2 |
The present technology provides compositions and methods for the treatment of diseases associated with abnormal lipid accumulation. In some embodiments, the present technology also provides methods of treating lipodystrophy, and disorder...
|
|
WO/2021/201109A1 |
Provided is an L-glucose derivative represented by general formula (1). [In formula (1), X1 represents a -SAuR1 group, and X2, X3, X4, and X5 each independently represent a -OR2 group, a -NH2 group, or a fluorine atom. R1 represents a li...
|
|
WO/2021/201790A1 |
The present invention discloses and claims a novel anthracene-functionalized dual cross-linked glycan-based hydrogel with reversible crosslinking, a preparation method thereof, and a use thereof for delivery system of bioactive molecules.
|
|
WO/2021/193928A1 |
The problem addressed by the present invention is to provide a pharmaceutical drug for destroying tumor cells. According to the present invention, provided is a pharmaceutical drug for destroying tumor cells, the pharmaceutical drug cont...
|
|
WO/2021/193744A1 |
The present disclosure includes a system for treating cancer, the system comprising: an extracorporeal circulation device that is for collecting and returning the blood of a subject, and that includes a blood circuit and a blood pump; an...
|
|
WO/2021/191643A1 |
The primary object of the invention is deuterium-depleted water (DDW) with a deuterium content of 0.01 to 135 ppm for use in normalisation of leptin level in a mammal, preferably in a human. In a preferred embodiment of the invention, DD...
|
|
WO/2021/192113A1 |
The present disclosure involves a system, etc., said system being for treating cancer and comprising an extracorporeal circulation device that comprises a blood circuit and a blood pump for collecting and returning blood of a subject and...
|
|
WO/2021/195493A1 |
Methods, devices, and systems for temperature management of a patient having a viral infection or suffering from sepsis are disclosed. Methods, devices, and systems for raising a regional temperature of the patient to and/or actively mai...
|
|
WO/2021/188467A1 |
The present disclosure relates generally to detection of long noncoding RNA (lncRNA) molecules in a sample or diagnosis of subject based upon detection of long noncoding RNAs in a sample, specifically to identify and use of molecular bio...
|
|
WO/2021/187868A1 |
Disclosed are a compound, a photosensitizer comprising same, a composition for diagnosing or treating a tumor targeting mitochondria, and a photodynamic treatment method using the composition. The compound may be represented by the above...
|
|
WO/2020/204193A9 |
Provided is a novel composition which comprises an ultraviolet wavelength conversion substance, a dispersant, an ultraviolet absorbing agent and/or an ultraviolet scattering agent and an oily component, wherein the content of the dispers...
|
|
WO/2021/181132A1 |
The invention concerns a sonosensitizing agent (ASS) based on zinc oxide (ZnO) micro- and/ or nanoparticles activated by external pressure stimuli, specifically by ultrasounds (US). The invention also concerns a method of ultrasonic acti...
|
|
WO/2021/180780A1 |
Treatment and/or diagnosis of a cancer type characterized by expressing zinc transporter ZIP4. The present invention is directed to nanocarriers functionalized with a ligand capable to bind to the extracellular domain of zinc transporter...
|
|
WO/2021/183931A1 |
A method of inducing cell death in a subject includes administering to the subject a plurality of cell targeted nanobubbles that are internalized by the target cell and insonating nanobubbles internalized into the target cell with ultras...
|
|
WO/2021/179064A1 |
A series of novel molecular conjugates is disclosed herein, consisting of a photosensitizer moiety chemically bonded to at least one diazirine moiety. Such conjugates react in air and/or water with non-coherent visible light to form sing...
|
|
WO/2021/174868A1 |
A preparation method for a chlorin nanometer photosensitizer, comprising the following steps: mixing a chlorin photosensitizer and tris(hydroxymethyl)aminomethane in an organic solvent, and carrying out self-assembly on the chlorin photo...
|
|
WO/2021/174195A2 |
The present application is directed to a combination therapy comprising a thyroid hormone receptor beta-1 (ΤΚβ) agonist, and a primary cancer therapeutic. Methods of treating cancer and inducing differentiation in a population of canc...
|
|
WO/2021/169661A1 |
The present invention belongs to the field of photodynamic anti-microbial technology, and relates to BODIPY compounds of formula (I) or (II), particularly 4-position cation double-substituted BODIPY compounds, a preparation method theref...
|
|
WO/2021/173459A1 |
Methods are provided that utilize irradiation to selectively induce release of granules (such as granules containing cytokines or other therapeutically active substances) from platelets. Such irradiation can be performed ex vivo or in vi...
|
|
WO/2021/170915A1 |
Method and kit for topical treatment of a skin infection, in particular of superficial skin infections, caused by Staphylococcus aureus. The method comprises the steps of applying a photosensitizer to at least a part of the skin affected...
|
|
WO/2021/173468A1 |
Methods for producing and utilizing primed platelets are provided, in which platelets are primed for release of specific granule types and/or active compounds by irradiation, for example with electromagnetic radiation, an electrical fiel...
|
|
WO/2021/164795A1 |
The present invention relates to new pyrazole-indole derivatives conjugated by ethene, buta-1,3-diene or ethyne linkers and containing substituents at R1, R2 and R3 positions of the general formula I which can be used in photodynamic the...
|
|
WO/2021/167022A1 |
[Problem] To provide a probe capable of inducing the destruction of actin fiber in a spatiotemporally selective manner, and a method using the same. [Solution] Provided is a compound represented by formula (I) or a salt thereof.
|
|
WO/2021/165876A1 |
The present inventions relates to a method for vision restoration comprising the steps of expressing a temperature-sensitive transient receptor potential (TRP) channel having an extracellular tag in the retina of a subject and of contact...
|
|
WO/2021/160659A1 |
Use of a suspension of gas-filled microbubbles comprising a fatty acids di-ester of phosphatidylcholine (PC), a pegylated phosphatidylethanolamines (PE-PEG) and a fatty acid in a therapeutic method, wherein said suspension is administere...
|
|
WO/2021/162375A1 |
The present invention relates to an exosome comprising a photocleavable protein, and a use thereof. An exosome according to the present invention contains a fusion protein comprising a blue fluorescent protein (TagBFP), a photocleavable ...
|
|
WO/2021/146428A9 |
Provided herein are microbubble compositions comprising nitro-fatty acids and/or esters thereof, such as amphiphilic esters or allyl esters thereof. Also provided are methods of reducing local inflammation at a site in a patient comprisi...
|
|
WO/2021/162187A1 |
The present invention relates to a magnetic nanoparticle heating method using resonance, comprising the steps of: (a) providing magnetic nanoparticles; applying a direct current magnetic field to the magnetic nanoparticles; and applying ...
|
|
WO/2021/157655A1 |
The present invention addresses the problem of providing a novel phthalocyanine dye to be used in photoimmunotherapy, a method for producing same, and a conjugate between a peptide or an antibody and said phthalocyanine dye. The present ...
|
|
WO/2021/156718A2 |
Skin-associated autoimmune diseases are common these days. A method and composition for microbiome based amelioration of skin associated autoimmune inflammatory diseases has been provided. The composition is made of at least one or more ...
|
|
WO/2021/155025A1 |
A method for treating type 2 diabetes (T2D) is provided. The method comprises diagnosing a subject as suffering from T2D or as being pre-diabetic; monitoring the response to glucose stimulation of at least one islet in the pancreas of th...
|
|
WO/2021/154958A1 |
The present disclosure provides novel methods of maturing an AVF at the time of fistula creation comprising administering to an AVF a composition comprising at least one active agent chosen from a Compound of Formula (I) and pharmaceutic...
|
|
WO/2021/150109A1 |
The current invention relates to a combination therapy comprising administering the antimitotic agent ABT-751 to a subject and delivering ionizing radiation to the same subject for the treatment of a brain tumor. Provided is for ABT-751 ...
|
|
WO/2021/146471A2 |
The invention provides, for the first time, strategies to inhibit the killing of transplanted cells by activated polymorphonuclear cells (PMNs) of the recipient. Multiple different modes for PMN inhibition are provided and one or more ag...
|
|
WO/2021/143829A1 |
Disclosed are a non-peripheral quaternary ammonium group modified zinc phthalocyanine and method for preparation thereof and application thereof, belonging to the field of photodynamic medicine or photosensitizer preparation. The non-per...
|
|
WO/2021/142884A1 |
Disclosed is the use of aspirin in the preparation of a platelet-targeted drug delivery system. Aspirin is co-incubated with a platelet in vitro to inhibit the aggregation and deformation of the platelet, so that the platelet is used as ...
|
